[go: up one dir, main page]

CY2010015I2 - Φθοροαλκοξυ-υποκατεστημενα βeναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης - Google Patents

Φθοροαλκοξυ-υποκατεστημενα βeναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης

Info

Publication number
CY2010015I2
CY2010015I2 CY2010015C CY2010015C CY2010015I2 CY 2010015 I2 CY2010015 I2 CY 2010015I2 CY 2010015 C CY2010015 C CY 2010015C CY 2010015 C CY2010015 C CY 2010015C CY 2010015 I2 CY2010015 I2 CY 2010015I2
Authority
CY
Cyprus
Prior art keywords
benamides
fluoroalkoxy
cyclic
substituted
phosphodiesterase inhibitors
Prior art date
Application number
CY2010015C
Other languages
English (en)
Other versions
CY2010015I1 (el
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4223466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2010015(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY2010015I2 publication Critical patent/CY2010015I2/el
Publication of CY2010015I1 publication Critical patent/CY2010015I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CY2010015C 1993-07-02 2010-09-29 Φθοροαλκοξυ-υποκατεστημενα βεναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης CY2010015I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH199693 1993-07-02
PCT/EP1994/002169 WO1995001338A1 (de) 1993-07-02 1994-07-02 Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Publications (2)

Publication Number Publication Date
CY2010015I2 true CY2010015I2 (el) 2011-02-02
CY2010015I1 CY2010015I1 (el) 2011-02-02

Family

ID=4223466

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0300082A CY2389B1 (en) 1993-07-02 2003-11-11 Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors.
CY2010015C CY2010015I1 (el) 1993-07-02 2010-09-29 Φθοροαλκοξυ-υποκατεστημενα βεναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY0300082A CY2389B1 (en) 1993-07-02 2003-11-11 Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors.

Country Status (27)

Country Link
US (1) US5712298A (el)
EP (1) EP0706513B1 (el)
JP (1) JP3093271B2 (el)
KR (1) KR100331255B1 (el)
CN (1) CN1046939C (el)
AT (1) ATE217612T1 (el)
AU (1) AU687087B2 (el)
CA (1) CA2165192C (el)
CY (2) CY2389B1 (el)
CZ (1) CZ290266B6 (el)
DE (2) DE59410119D1 (el)
DK (1) DK0706513T3 (el)
ES (1) ES2176252T3 (el)
FI (1) FI112864B (el)
FR (1) FR10C0052I2 (el)
HU (1) HU220041B (el)
LU (1) LU91709I2 (el)
LV (1) LV13074B (el)
NO (2) NO305598B1 (el)
NZ (1) NZ271316A (el)
PL (1) PL178314B1 (el)
PT (1) PT706513E (el)
RU (1) RU2137754C1 (el)
SG (1) SG143011A1 (el)
SI (1) SI0706513T1 (el)
SK (1) SK283263B6 (el)
WO (1) WO1995001338A1 (el)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
ES2188983T4 (es) * 1996-08-19 2004-06-01 Altana Pharma Ag Nuevas benzofuran-4-carboxamidas.
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP0941086A4 (en) * 1996-11-01 2000-07-12 Nitromed Inc NITROSIZED AND NITROSYLATED PHOSPHODIESTERASE INHIBITING COMPOUNDS, COMPOSITIONS AND THEIR USE
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
AU734122B2 (en) * 1997-02-17 2001-06-07 Takeda Gmbh Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
US6531493B1 (en) 1999-03-10 2003-03-11 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
AU4558800A (en) * 1999-05-04 2000-11-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination comprising roflumilast and a pde-3 inhibitor
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
DE10043074A1 (de) 2000-09-01 2002-03-14 Aventis Cropscience Gmbh Herbizid wirksame Benzoylcyclohexandione
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
ATE303384T1 (de) 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
EP1431267A4 (en) * 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
RU2227797C2 (ru) * 2002-03-29 2004-04-27 Пермская государственная фармацевтическая академия 4-метил-2-пиридиламид тетрахлорфталевой кислоты, проявляющий гипертензивную активность
JP2005528418A (ja) * 2002-05-07 2005-09-22 アルタナ　ファルマ　アクチエンゲゼルシャフト 気道疾患を治療するための新規組み合わせ
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
BR0310061A (pt) * 2002-05-16 2005-03-01 Pharmacia Corp Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
DK2020243T3 (en) * 2002-05-28 2018-11-19 Astrazeneca Ab Pharmaceutical composition which can be applied topically
BR0313000A (pt) 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US20060019932A1 (en) * 2002-09-06 2006-01-26 Mancini Joseph A Treatment of rheumatoid arthritis by inhibition of pde4
KR20050057175A (ko) * 2002-09-20 2005-06-16 알콘, 인코퍼레이티드 안구건조증 치료용 사이토카인 합성 저해제의 용도
US6822114B1 (en) * 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
DE60317918T2 (de) 2002-10-23 2009-01-29 Glenmark Pharmaceuticals Ltd. Tricyclische verbindungen zur behandlung von entzündlichen und allergischen erkrankungen verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
CN100513397C (zh) * 2002-11-19 2009-07-15 记忆药物公司 磷酸二酯酶4抑制剂
DE60321953D1 (de) * 2002-11-27 2008-08-14 Nycomed Gmbh Neue synergistische zusammensetzung enthaltend roflumilast und formoterol
TW200426138A (en) * 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
NZ542882A (en) 2003-04-11 2007-10-26 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
WO2004098598A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098595A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098597A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
EA012279B1 (ru) 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2005026095A1 (en) * 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
WO2005046676A1 (en) * 2003-11-12 2005-05-26 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
ATE542546T1 (de) 2003-11-20 2012-02-15 Astellas Pharma Inc Pde 4 inhibitoren zur behandlung der interstitiellen cystitis
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2005074918A1 (en) * 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
HRP20130828T1 (en) 2004-03-03 2013-09-30 Takeda Gmbh Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
BRPI0513286A (pt) * 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2583497A1 (en) 2004-10-13 2006-04-20 Glenmark Pharmaceuticals S.A. Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤
EP1813284A1 (en) * 2004-10-13 2007-08-01 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition
US7943634B2 (en) 2004-12-17 2011-05-17 Glenmark Pharmaceuticals S.A. Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
EA016037B1 (ru) 2005-04-19 2012-01-30 Никомед Гмбх Рофлумиласт для лечения лёгочной гипертензии
WO2006120176A2 (en) * 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942882A2 (en) * 2005-10-24 2008-07-16 Novartis AG Combination of histone deacetylase inhibitors and radiation
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
ES2389231T3 (es) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) * 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
US20100056791A1 (en) 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
CN103463086B (zh) 2007-05-16 2015-10-21 塔科达有限责任公司 作为pde4抑制剂的吡唑啉酮衍生物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
SG10201406210PA (en) 2008-02-01 2014-11-27 Orchid Res Lab Ltd Novel heterocycles
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
NZ603895A (en) 2010-06-24 2014-10-31 Leo Pharma As Novel phosphodiesterase inhibitors
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102093194B (zh) * 2010-12-24 2014-01-08 江苏先声药物研究有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN107090016A (zh) 2011-03-01 2017-08-25 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
CN102690194B (zh) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102276522B (zh) * 2011-06-15 2013-04-17 无锡泓兴生物医药科技有限公司 一种制备罗氟司特的方法及其中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
HK1198251A1 (en) * 2011-10-21 2015-03-20 奇斯药制品公司 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
WO2013072938A2 (en) 2011-11-09 2013-05-23 Mylan Laboratories Ltd An improved process for the preparation of roflumilast
WO2013081565A1 (en) 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
WO2013077830A1 (en) 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013131255A1 (en) 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103630613B (zh) * 2012-08-21 2015-08-05 北大方正集团有限公司 分离并检测罗氟司特及其中间体的方法
EP2909177B1 (en) 2012-10-17 2017-03-29 Interquim, S.A. Process for preparing roflumilast
CN110403922A (zh) 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
WO2014117947A1 (en) 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
MX2015009677A (es) 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida novedosos.
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CN103304475A (zh) * 2013-06-13 2013-09-18 湖南千金湘江药业股份有限公司 苯甲酰胺化合物及其制备方法和用途
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
WO2015018534A1 (en) 2013-08-09 2015-02-12 Grünenthal GmbH Novel substituted condensed pyrimidine compounds
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
JP2017515840A (ja) 2014-05-12 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 感染症を治療するためのダニリキシンを含む医薬組成物
AR101196A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Compuestos de pirimidina sustituidos
AR101197A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas
AR101198A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
CN104130116B (zh) * 2014-08-18 2015-11-11 朱丽平 一种制备罗氟司特中间体的方法
ES2777550T3 (es) 2014-10-24 2020-08-05 Hisamitsu Pharmaceutical Co Profármaco de roflumilast
CN104447245B (zh) * 2014-10-29 2017-06-06 成都森科制药有限公司 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
KR20170034707A (ko) 2015-09-21 2017-03-29 한미약품 주식회사 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN105523954B (zh) * 2016-02-05 2017-07-18 徐江平 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
PT3700529T (pt) 2017-10-23 2025-09-17 Boehringer Ingelheim Int Nova combinação de agentes ativos para o tratamento das doenças pulmonares intersticiais fibrosantes progressivas (dpi-fp
AU2019281888B2 (en) 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
BR112022015104A2 (pt) 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
WO2021213455A1 (zh) 2020-04-23 2021-10-28 浙江养生堂天然药物研究所有限公司 药物组合及其用途
CN111777550A (zh) * 2020-06-01 2020-10-16 山东希尔康泰药业有限公司 罗氟司特结晶性粉末原料药生产制备方法
MX2023006602A (es) 2020-12-04 2023-08-07 Arcutis Biotherapeutics Inc Formulación tópica de roflumilast que tiene propiedades antimicoticas.
WO2022156727A1 (zh) 2021-01-21 2022-07-28 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2022173923A1 (en) 2021-02-10 2022-08-18 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
WO2023129892A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical aerosol foams
WO2023129215A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025054483A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308239A1 (de) * 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
JPS62158253A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
SU1512053A1 (ru) * 1988-01-29 1991-01-15 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 2-Окси-3,5-дигалоид-N-[3-хлор-4-(4-галоиднафтокси-1)-фенил]-бензамиды, обладающие активностью при экспериментальном описторхозе и гименолепидозе
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0581805A1 (de) * 1991-04-26 1994-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
ES2102036T3 (es) * 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
EP0652868B1 (en) * 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE

Also Published As

Publication number Publication date
AU7490794A (en) 1995-01-24
CN1126468A (zh) 1996-07-10
HU220041B (hu) 2001-10-28
RU2137754C1 (ru) 1999-09-20
EP0706513A1 (de) 1996-04-17
CA2165192C (en) 2001-04-24
DE59410119D1 (de) 2002-06-20
HUT73232A (en) 1996-07-29
ATE217612T1 (de) 2002-06-15
KR100331255B1 (ko) 2002-10-25
FI112864B (fi) 2004-01-30
HU9503541D0 (en) 1996-02-28
NZ271316A (en) 1997-11-24
PL311820A1 (en) 1996-03-18
SK283263B6 (sk) 2003-04-01
FI956333A0 (fi) 1995-12-29
DK0706513T3 (da) 2002-09-09
NO2010018I1 (no) 2010-10-18
NO2010018I2 (el) 2011-10-17
NO955211L (no) 1995-12-21
WO1995001338A1 (de) 1995-01-12
PL178314B1 (pl) 2000-04-28
US5712298A (en) 1998-01-27
LV13074B (en) 2004-03-20
HK1011690A1 (en) 1999-07-16
SG143011A1 (en) 2008-06-27
CA2165192A1 (en) 1995-01-12
ES2176252T3 (es) 2002-12-01
FR10C0052I1 (el) 2011-01-14
NO955211D0 (no) 1995-12-21
DE122010000043I1 (de) 2011-01-27
CZ290266B6 (cs) 2002-06-12
CY2389B1 (en) 2004-09-10
CY2010015I1 (el) 2011-02-02
JP3093271B2 (ja) 2000-10-03
JPH08512041A (ja) 1996-12-17
CZ196A3 (en) 1996-06-12
KR960703400A (ko) 1996-08-17
FI956333A7 (fi) 1995-12-29
LU91709I2 (fr) 2010-09-21
CN1046939C (zh) 1999-12-01
SK161795A3 (en) 1996-07-03
AU687087B2 (en) 1998-02-19
PT706513E (pt) 2002-10-31
FR10C0052I2 (el) 2011-11-25
EP0706513B1 (de) 2002-05-15
NO305598B1 (no) 1999-06-28
SI0706513T1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CY2010015I2 (el) Φθοροαλκοξυ-υποκατεστημενα βeναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης
FI942333A0 (fi) Silyylillä silloitetut metalloseenit ja niiden käyttö
FI942682L (fi) Bisfluorenyylimetalloseenit ja niiden käyttö
DK0922697T3 (da) Substituerede pyrazolylbenzensulfonamider og anvendelse deraf som cyclooxygenase II-inhibitorer
NO942064D0 (no) yminhibitorer
FI942744A7 (fi) Metalloseeneja ja siihen liittyviä menetelmiä
FI962246A7 (fi) Apoptoosia inhiboivat koostumukset, koostumusten puhdistusmenetelmät j a niiden käyttö
FI945625L (fi) Indolokarbatsoli-imidit ja niiden käyttö
NO991776D0 (no) Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer
FI961599A7 (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
FI970317A7 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
FI944624L (fi) 4-aryyliaminobentsopyraani- ja niiden kaltaisia yhdisteitä
FI962022L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
DE69418203D1 (de) Zementiermittel und ihre verwendung
FI933877A0 (fi) Haollfast kompositroer pao termoplastbasis
FI962021L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
FI962481L (fi) 4-bentsoyyli-isokatsolit ja niiden käyttö herbisideinä
FI935011L (fi) Mellanvaeggsystem i synnerhet foer hyttdaeck pao fartyg
FI970318L (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä
FI956318L (fi) Uudet ristisitojat ja niiden käyttö
KR950000189U (ko) 다목적 활동화
SE9304032D0 (sv) New use
SE9302796D0 (sv) New use
SE9302709D0 (sv) New use
SE9300963D0 (sv) New use